Jupiter Life Line Hospitals Ipo Subscribed Over 63 Times On Day 3

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Jupiter Life Line Hospitals IPO subscribed over 63 times on Day 3

ri-calendar-2-lineSep 11, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

The initial public offering of Jupiter Lifeline Hospital IPO received strong response from the investors and was subscribed 63.72 times on the final day. The IPO of multi-speciality healthcare provider opened for subscription on Wednesday, September 6.

 

Jupiter Lifeline Hospital IPO received overwhelming response from non-institutional investors (NIIS) and Qualified institutional buyers (QIBs) on day 3. Retail investors' portion saw stable response. 

 

The retail investors portion was subscribed 7.73 times, followed by the NII portion at 34.75 times. The QIBs portion was subscribed 187.32 times on the final day.

 

According to data from NSE, the investors made bids for 54 crore equity shares, compared to the 84 lakh equity shares offered for the subscription.

 

The company sold its shares in the range of Rs 695-735 per share during the three-day bidding process.

Related News

News Thumbnail
Ipo

IRM Energy shares list at 5.5% discount to issue price

1 mins read. October 26, 2023 at 04:57 AM

News Thumbnail
Ipo

PayU Plans India IPO Worth $500 Million

1 mins read. October 11, 2023 at 09:57 AM

Related Blogs

Stock chartIPO

CKK Retail Mart IPO Allotment Status Online

0 people read

5 mins read . Jan 30, 2026

Stock chartIPO

NFP Sampoorna Foods IPO Allotment Status Online

0 people read

4 mins read . Jan 30, 2026

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions